Dr. Reddy’s facility inspection by the USFDA closes with VAI status; the company is committed to addressing all inspection observations.

• USFDA issued an Establishment Inspection Report (EIR) post-GMP audit; inspection formally closed under regulatory guidelines.
• Two observations cited in the May 2025 inspection, Dr. Reddy’s, are to be resolved within the required timeline.
• Q4FY25 profit rose 22% YoY to ₹1,594 crore; revenue up 20% at ₹8,506 crore; stock down 0.44%.